Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Management of metabolic-associated fatty liver disease: The diabetology perspective
Mohammad Sadiq Jeeyavudeen, Shahanas K A Khan, Sherouk Fouda, et al.
World Journal of Gastroenterology (2023) Vol. 29, Iss. 1, pp. 126-143
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Puerarin ameliorates metabolic dysfunction-associated fatty liver disease by inhibiting ferroptosis and inflammation
Mengmeng Yang, Longqing Xia, Jia Song, et al.
Lipids in Health and Disease (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 31
From liver to hormones: The endocrine consequences of cirrhosis
Juan Eduardo Quiroz‐Aldave, Elman Rolando Gamarra‐Osorio, María del Carmen Durand‐Vásquez, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 9, pp. 1073-1095
Open Access | Times Cited: 7
Associations between metabolic dysfunction-associated fatty liver disease, chronic kidney disease, and abdominal obesity: a national retrospective cohort study
Chao Cen, Zhongwen Fan, Xinjiang Ding, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Thyme, oregano, and rosemary: herbs and food supplements for the management of metabolic associated fatty liver disease
Hamza Elbouny, Ayoub Amssayef, Rania Benjamaa, et al.
Nutrire (2025) Vol. 50, Iss. 1
Closed Access
Efficacy and safety of resmetirom in MASLD and MASH: network meta-analysis of randomized clinical trials
Hazem Ayesh, Azizullah Beran, Sajida Suhail, et al.
Journal of Basic and Clinical Physiology and Pharmacology (2025)
Closed Access
MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development
Farah Khaznadar, Omar Khaznadar, Ana G. Petrovic, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 7, pp. 6300-6314
Open Access | Times Cited: 4
The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment
Eleni Michalopoulou, J Thymis, Stamatios Lampsas, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 2, pp. 428-428
Open Access
Beyond Glucose: Empagliflozin’s Impact on Fatty Liver in Patients with Type 2 Diabetes; A True Game Changer
Qamar Sajad, Khurshid Khan, Aijaz Zeeshan Khan, et al.
Indus journal of bioscience research. (2025) Vol. 3, Iss. 2, pp. 193-198
Closed Access
Dapansutrile Regulates Mitochondrial Oxidative Stress and Reduces Hepatic Lipid Accumulation in Diabetic Mice
Ying Wu, Jiaqiang Zhou
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 3, pp. 148-148
Open Access
Accurate and sensitive low-density lipoprotein (LDL) detection based on the proximity ligation assisted rolling circle amplification (RCA)
Xingyu Zhang, Jie Li, Mei Yang, et al.
Analytical Methods (2024) Vol. 16, Iss. 13, pp. 1894-1900
Closed Access | Times Cited: 3
Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment
Yuping Ding, Quanjun Deng, Mei Yang, et al.
Diabetes Metabolic Syndrome and Obesity (2023) Vol. Volume 16, pp. 3303-3329
Open Access | Times Cited: 8
Metabolic-Associated Fatty Liver Disease and Diabetes
Nitin Kapoor, Sanjay Kalra
Endocrinology and Metabolism Clinics of North America (2023) Vol. 52, Iss. 3, pp. 469-484
Closed Access | Times Cited: 7
Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and MACCEs in Patients with Diabetic Foot Ulcers: An Ambispective Longitudinal Cohort Study
Xiuxian Huang, Zhengming Li, Zhenwei Zhai, et al.
Diabetes Metabolic Syndrome and Obesity (2024) Vol. Volume 17, pp. 1119-1130
Open Access | Times Cited: 2
Metabolic dysfunction-associated steatotic liver disease and diabetes: the cross-talk between hepatologist and diabetologist
Ming‐Lun Yeh, Jee‐Fu Huang, Chia‐Yen Dai, et al.
Expert Review of Gastroenterology & Hepatology (2024) Vol. 18, Iss. 8, pp. 431-439
Closed Access | Times Cited: 2
Bioactive dipeptides mitigate high-fat and high-fructose corn syrup diet-induced metabolic-associated fatty liver disease via upregulation of Nrf2/HO-1 expressions in C57BL/6J mice
Vipul Wayal, Chang‐Chi Hsieh
Biomedicine & Pharmacotherapy (2023) Vol. 168, pp. 115724-115724
Open Access | Times Cited: 4
Non-alcoholic fatty liver disease: a current challenge of interdisciplinary research
Elena V. Biryukova
Meditsinskiy sovet = Medical Council (2024), Iss. 6, pp. 72-80
Open Access | Times Cited: 1
Dyslipidemia, Cholangitis and Fatty Liver Disease: The Close Underexplored Relationship: A Narrative Review
Salvatore Greco, Michele Campigotto, Andrea D’Amuri, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 9, pp. 2714-2714
Open Access | Times Cited: 1
MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development
Farah Khaznadar, Omar Khaznadar, Ana G. Petrovic, et al.
(2024)
Open Access | Times Cited: 1
Metabolic-associated fatty liver disease and older age
И. С. Сабиров, O. O. Karshina, А. И. Сабирова, et al.
Experimental and Clinical Gastroenterology (2024), Iss. 3, pp. 25-32
Open Access | Times Cited: 1
Management of Metabolic-Associated Fatty Liver Disease
Kirthika Venkatesan, Nisha Nigil Haroon
Endocrinology and Metabolism Clinics of North America (2023) Vol. 52, Iss. 3, pp. 547-557
Closed Access | Times Cited: 4
Management of depression/anxiety in patients with chronic liver disease
Mauro A. Garcia-Altieri, Keila Carrera-Mejias, Rubén Hernáez
Clinical Liver Disease (2024) Vol. 23, Iss. 1
Open Access
Proinflammatory interleukins 2, 6 and tumor necrosis factor alpha in patients with hypertension and diabetes mellitus depending on the presence of metabolic-associated liver steatosis
О. М. Радченко, O.J. Komarytsia, M.O. Borovets, et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) (2024) Vol. 20, Iss. 3, pp. 200-203
Open Access
Prevalence and risk factors for metabolic-associated fatty liver disease in adult participants attending tertiary hospitals in Dodoma, Tanzania. This was a cross-sectional study
Francis Msagati, Baraka Alphonce, Emmanuel Sindato
Research Square (Research Square) (2024)
Open Access
Metabolic-Associated Fatty Liver Disease and Cognitive Performance in Type 2 Diabetes: Basal Data from the Phytate, Neurodegeneration and Diabetes (PHYND) Study
Antelm Pujol, Pilar Sanchís, María Isabel Tamayo‐Navarrete, et al.
Biomedicines (2024) Vol. 12, Iss. 9, pp. 1993-1993
Open Access
Polymorphism of PNPLA3 and TM6SF2 genes in patients with nonalcoholic fatty liver disease resident at Gomel region
N. S. Branovitskaya
Health and Ecology Issues (2024) Vol. 21, Iss. 3, pp. 45-51
Closed Access
Page 1 - Next Page

Scroll to top